What this study is
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
What's being tested
- Adjustable Continence Therapy for Women (ACT)
Intervention · DEVICE
Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
Study details
- Official title
- A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
- Sponsor
- Uromedica
- Conditions
- Urinary Incontinence · Urinary Incontinence,Stress
- Enrolling
- 167 people
- Starts
- 2021-01-26
- Est. completion
- 2032-05-31
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 22 Years and overSex FEMALEHealthy volunteers Not acceptedYou may qualify if
- Female at least 22 years old
- Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
- Provocative pad weight of greater than 11.0 grams
- Candidate for surgical intervention
- Negative urinalysis
- Normal cystourethroscopy
- Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
- Willing and able to sign informed consent and comply with trial follow-up requirements
You can't join if
- Pregnant or lactating
- Life expectancy of less than 5 years
- Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
- Has auto-immune disease
- Undergoing radiation therapy
- Active urinary tract infection
- Detrusor instability refractory to medication
- Reduced bladder compliance as defined by a cystometrogram
- Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
- Has, had, or is suspected of having bladder cancer
- History of bladder stones
- Urethral stricture evidenced during cystourethroscopy
- Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
- Has a diathesis, hemophilia, or a bleeding disorder
- Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
- Had prior pelvic radiotherapy
- Had a prior artificial urinary sphincter implanted
- Has a neurogenic condition known to affect bladder/sphincter function
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (8)
7 openUniversity of Colorado
Denver, Colorado, United States
- Andrea Pina · Contactandrea.pinalimones@cuanschutz.edu
- Brian Flynn, MD · Principal investigator
RecruitingIdaho Urologic Institute, PA
Meridian, Idaho, United States
- Karrie Fox · Contactkarried@idurolog.com
- Brian Mihm · Contactbmihm@idurology.com
- Lisa Parillo, MD · Principal investigator
RecruitingCHI Health Research Center
Omaha, Nebraska, United States
- Jodi Salvatori, RN, BSN · Contact402-343-8511jodi.salvatori@commonspirit.org
- Michael Feloney, MD · Principal investigator
RecruitingPenn State University
Hershey, Pennsylvania, United States
- Jocelyn Chavla · Contactjchavla@pennstatehealth.psu.edu
- Arturo Garcia Mora, MD · Principal investigator
RecruitingSaint Lukes Health System
Independence, Missouri, United States
Active, not recruiting
3 sites outside the US
Hôpital de la Conception - Marseille
Marseille, France
- Nassima Rabah · Contact+33 (0)4 91 38 11 34nassima.rabah@ap-hm.fr
- Gilles Karsenty, MD · Principal investigator
RecruitingCHU de Nantes
Nantes, France
- Amanda Simon · Contact+33 2 40 08 39 10amanda.simon@chu-nantes.fr
- Marie-Aimee Perrouin-Verbe, MD · Principal investigator
RecruitingPitié Salpêtrière University Hospital Paris
Paris, France
- Kamilia Zedek · Contact+33 (01) 84 82 83 23kamilia.zedek@aphp.fr
- Emmanuel Chartier-Kastler, MD · Principal investigator
Recruiting
Study team
Sponsor
Uromedica
Study ID UM08
Study director
Philip Johnson, PhD
Uromedica, Inc.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.